Evidence map›Paper›PMID 41465584›Full record

ReviewInternational journal of molecular sciences2025

Significance of EVs in Prostate Cancer Bone Metastases.

Kagenori Ito, Takaaki Tamura, Fumihiko Urabe, Shinichi Sakamoto, Takahiro Kimura, Shin Egawa, Takahiro Ochiya

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kagenori ItoDepartment of Urology, The Jikei University School of Medicine, Tokyo 105-8471, Japan.ORCID 0000-0002-4970-1727
Takaaki TamuraDepartment of Urology, Chiba University, Chiba 263-8522, Japan.
Fumihiko UrabeDepartment of Urology, The Jikei University School of Medicine, Tokyo 105-8471, Japan.ORCID 0000-0002-2599-8183
Shinichi SakamotoDepartment of Urology, Chiba University, Chiba 263-8522, Japan.ORCID 0000-0002-7508-7521
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo 105-8471, Japan.ORCID 0000-0002-5673-1553
Shin EgawaDepartment of Urology, The Jikei University School of Medicine, Tokyo 105-8471, Japan.
Takahiro OchiyaDepartment of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, Tokyo 160-0023, Japan.

Funding

Japan Society for the Promotion of Science (JSPS) KAKENHI JP24K18590
6 · The paper itself

Abstract

Prostate cancer (PCa) exhibits a unique propensity to metastasize to bone, where it predominantly generates osteoblastic lesions. The formation of these lesions is a complex and dynamic process driven by reciprocal interactions between tumor cells and the bone microenvironment. Emerging evidence indicates that extracellular vesicles (EVs) play pivotal roles in the establishment of metastatic colonies and disease progression, as well as in local tumor-bone interactions. Through their diverse cargos, including proteins, lipids, and non-coding RNAs, EVs mediate bidirectional communication that regulates osteoclastogenesis, osteoblast activation, and osteocyte function, ultimately reshaping the bone niche to favor tumor growth. Importantly, EVs exhibit dual and context-dependent functions, acting either as promoters or suppressors of malignancy depending on the cellular source and microenvironmental context. These insights highlight EVs not only as mechanistic drivers of PCa bone metastases but also as promising therapeutic targets. Approaches aimed at modulating EV biogenesis, eliminating deleterious EVs, or harnessing EVs as drug delivery vehicles hold significant potential for advancing treatment strategies against PCa bone metastases.

Indexed as

Bone NeoplasmsExtracellular VesiclesProstatic NeoplasmsAnimalsHumansMaleTumor Microenvironmentbone metastasisextracellular vesiclesosteoblastosteoclastprostate cancer

Identifiers

PMID41465584
PMCPMC12733577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.